Travere Therapeutics (TVTX) Operating Expenses (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Operating Expenses came in at $164.1 million in Q1 2026, up 31.92% YoY from $124.4 million in Q1 2025, and up 1.23% on a QoQ basis from $162.1 million in Q4 2025.
Travere Therapeutics (TVTX) Operating Expenses (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Operating Expenses data on file, last reported at $164.1 million in Q1 2026.
- Quarterly Operating Expenses rose 31.92% year-over-year to $164.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $593.3 million (up 18.46% YoY) and the FY2025 annual result came in at $553.6 million, down 0.62% from the prior year.
- Operating Expenses advanced to $164.1 million in Q1 2026, from $162.1 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $180.6 million in Q1 2024 to a low of $95.4 million in Q1 2022.
- A 5-year average of $131.6 million and a median of $128.3 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 149.85% — and 2025, when it plunged 31.12%.
- Tracing TVTX's Operating Expenses over 5 years: stood at $116.0 million in 2022, then grew by 20.04% to $139.3 million in 2023, then retreated by 2.71% to $135.5 million in 2024, then grew by 19.62% to $162.1 million in 2025, then grew by 1.23% to $164.1 million in 2026.
- The last three Operating Expenses figures came in at $164.1 million (Q1 2026), $162.1 million (Q4 2025), and $139.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 165.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165.63 Mn |
| Mar 31, 2026 | 164.11 Mn |
| Dec 31, 2025 | 162.12 Mn |
| Sep 30, 2025 | 139.93 Mn |
| Jun 30, 2025 | 127.10 Mn |
| Mar 31, 2025 | 124.41 Mn |
| Dec 31, 2024 | 135.52 Mn |
| Sep 30, 2024 | 119.05 Mn |
| Jun 30, 2024 | 121.82 Mn |
| Mar 31, 2024 | 180.61 Mn |
| Dec 31, 2023 | 139.29 Mn |
| Sep 30, 2023 | 129.68 Mn |
| Jun 30, 2023 | 136.15 Mn |
| Mar 31, 2023 | 128.26 Mn |
| Dec 31, 2022 | 116.04 Mn |
| Sep 30, 2022 | 110.68 Mn |
| Jun 30, 2022 | 107.16 Mn |
| Mar 31, 2022 | 95.39 Mn |
| Dec 31, 2021 | 46.45 Mn |
| Sep 30, 2021 | 99.93 Mn |